Evidence map›Paper›PMID 38966638›Full record

ArticleFrontiers in immunology2024

Corrigendum: Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein.

Mark A Kroenke, Marta Starcevic Manning, Christina L Zuch de Zafra, Xinwen Zhang, Kevin D Cook, Michael Archer, Martijn P Lolkema, Jin Wang, Sarah Hoofring, Gurleen Saini and 7 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Mark A KroenkeClinical Immunology, Amgen, Thousand Oaks, CA, United States.
Marta Starcevic ManningTranslational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.
Christina L Zuch de ZafraTranslational Safety & Bioanalytical Sciences, Amgen, South San Francisco, CA, United States.
Xinwen ZhangClinical Pharmacology, Modeling, and Simulation, Amgen, South San Francisco, CA, United States.
Kevin D CookPharmacokinetics and Drug Metabolism, Amgen, South San Francisco, CA, United States.
Michael ArcherGlobal Safety, Amgen, Thousand Oaks, CA, United States.
Martijn P LolkemaEarly Development, Amgen, Thousand Oaks, CA, United States.
Jin WangTranslational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.
Sarah HoofringTranslational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.
Gurleen SainiTranslational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.
Famke AeffnerTranslational Safety & Bioanalytical Sciences, Amgen, South San Francisco, CA, United States.
Elizabeth AhernMedical Oncology, Monash Health, Clayton, VIC, Australia.
Elena Garralda CabanasResearch Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Ramaswamy GovindanDivision of Hematology and Oncology, Washington University Medical School, St. Louis, MO, United States.
Mun HuiChris O'Brien Lifehouse, Camperdown, NSW, Australia.
Shalini GuptaTranslational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.
Daniel T MytychClinical Immunology, Amgen, Thousand Oaks, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2024.1345473.].

Indexed as

anti-drug antibodiesIgEIL-21immunogenicitymuteinPD-1

Identifiers

PMID38966638
PMCPMC11222687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.